EW EW エドワ―ズライフサイエンス

 EWのチャート


 EWの企業情報

symbol EW
会社名 Edwards Lifesciences Corp (EW エドワ―ズライフサイエンス)
分野(sector)   
産業(industry)   
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 エドワーズ・ライフサイエンス(Edwards Lifesciences Corporation)は欠陥心臓弁の置換、または修復に応用する心臓弁システムおよび修復製品の製造者である。同社は構造的心疾患および重症ケアのモニタリングなどの患者中心のイノベーションに従事する。同社のセグメントは米国、ヨーロッパ、日本、他の地域を含む。同社の製品分野は外科心臓弁療法、経カテーテル心臓弁、およびクリティカルケアを含む。同社は入院中の患者の心臓血管機能を測定するために使用される血行動態モニタリングシステムを提供する。同社の経カテーテル心臓弁製品は米国、シンガポール、スイスに生産される。クリティカルケア製品はプエルトリコとドミニカ共和国にある施設で生産される。同社の子会社はEdwards Lifesciences Asset Management Corporation、Edwards Lifesciences CardiAQ LLC.、 Valtech Cardio Inc.とRed Hill Insurance Corporationを含む。  エドワ―ズ・ライフサイエンスは重度の循環器疾患治療用の医療器具メ―カ―。心臓弁膜症などの循環器疾患や心臓血管疾患、また、救命救急診療技術、抹消血管障害の治療に焦点を置く。主要製品は、弁膜症治療用心臓弁「カ―ペンタ―・エドワ―ズ・ペリマウント」、人工弁輪、肺動脈カテ―テルなど。製品は約100カ国で販売される。  
本社所在地 One Edwards Way Irvine CA 92614 USA
代表者氏名 Michael A. Mussallem
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 949-250-2500
設立年月日 36404
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 12800人
url www.edwards.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 1155.80000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 39817.57000
売上高 売上高(百万ドル) 3722.80000
企業価値(EV) 企業価値(EV)(百万ドル) 39454.87000
当期純利益 当期純利益(百万ドル) 747.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Edwards Lifesciences Corp revenues increased 8% to $3.72B. Net income before extraordinary items decreased 16% to $738M. Revenues reflect Transcatheter Heart Valve Therapy segment increase of 13% to $2.29B Critical Care segment increase of 12% to $674.5M United States segment increase of 8% to $2.06B Rest of the world segment increase of 14% to $396M.

 EWのテクニカル分析


 EWのニュース

   GOLDMAN SACHS: Buy these 24 high-growth stocks that are investing in cash cows for the future at the highest rates in the S&P 500  2021/05/04 14:54:00 Business Insider
Summary List Placement Investing in growth stocks can be a difficult game at the moment. Many have unthinkably high valuations thanks to things like low interest rates and heightened speculation, raising questions about how long their outperformance can last going forward. On the other hand, investing solely based on valuation isn't always necessarily the best approach either. Another way to identify companies that could do well in the future is by looking at how much they're investing in themselves and planting the seeds of future growth. In a recent note, a team of analysts at Goldman Sachs did just that, and came up with a list of firms outperforming the S&P 500 average in terms of investment for the future. To do so, they looked at how much a firm is investing in the future as a percentage of their operating cash flow while also factoring in asset depreciation. "High capex spending by itself can be a flawed measure of investment for future growth since many firms operate in asset-heavy industries and may barely invest at a rate faster than assets are depreciating," Goldman's Chief US Equity Strategist David Kostin said in the Monday note.
   Neurovascular Thrombectomy Devices Market Expected to Rise by a CAGR of 14.27% by 2026, Estimates DelveInsight  2021/04/26 17:30:00 Benzinga
LAS VEGAS , April 26, 2021 /PRNewswire/ -- DelveInsight's " Neurovascular Thrombectomy Devices Market and Competitive Insight Report " provides the current and forecast market and comprises Neurovascular Thrombectomy Devices market trends and key competitors. DelveInsight estimated the market to rise at a high CAGR over the study period of 2018 – 2026. Key Highlights of Neurovascular Thrombectomy Devices Market report : Thrombectomy is a procedure to reduce the blood clots in the blood vessels. These devices are used to treat the brain's blockage, which may occur for many reasons, such as atheroma and thrombus in one or more arteries. Stroke is the leading cause of disability, and 80% to 85% of stroke cases are ischemic . The blood clot may cause fatal complications if left untreated, as per the World Health Organization (WHO) . Mechanical Thrombectomy is one of the treatment procedure needed to treat ischemic stroke patients using neurovascular thrombectomy devices such as aspiration catheters or stent retrieval, or a combination of both.
   Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences By Investing.com  2021/04/22 12:04:46 Investing.com
Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences
   Edward Lifesciences Hits Record High After Earnings Beat, TAVR Forecast - TheStreet  2021/04/21 14:42:18 The Street
Edwards Lifesciences said its sees transcatheter aortic valve replacement (TAVR) sales rising as high as 20% this year.
   Cutting-edge firm with major Limerick plans hailed as ‘Great Place to Work’  2021/03/02 13:00:00 Limerick Leader
A FIRM which provides innovations for structural heart disease has received a top certification. Edwards Lifesciences Corporation, which currently employs 165 people in Shannon, and will ramp up to 600 staff when it opens its permanent facility in the National Technology Park, has received the Great
   Cutting-edge firm with major Limerick plans hailed as ‘Great Place to Work’  2021/03/02 13:00:00 Limerick Leader
A FIRM which provides innovations for structural heart disease has received a top certification. Edwards Lifesciences Corporation, which currently employs 165 people in Shannon, and will ramp up to 600 staff when it opens its permanent facility in the National Technology Park, has received the Great
   Prosthetic Heart Valve Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026 | Edwards Lifesciences Corporation, Medtronic plc.  2021/02/12 04:06:52 OpenPR
Prosthetic Heart Valve Market Report 2020-2026 incorporates a complete examination of the current market. The report begins with the fundamental Prosthetic Heart Valve industry review and afterward goes into every single detail. Mechanical heart valve is an artificial heart valve implanted
   egnite, Inc. Launches as a Digital Health Company to Help Hospital Systems Improve the Quality of Patient Care  2021/02/10 13:00:00 Business Wire
ALISO VIEJO, Calif.--(BUSINESS WIRE)--egnite, a digital healthcare company, launched today with the goal to improve care for structural heart disease patients by delivering actionable insights through intuitive digital health platforms, proprietary artificial intelligence (A.I.) powered analytics and deep clinical expertise. egnite’s flagship solution, CardioCare, was developed at Edwards Lifesciences, and achieved several key innovation milestones and commercial successes over the past six yea
   Latest Insights on Heart Valve Devices Market Post-COVID? Fact.MR New Report Analyzes | Edwards Lifesciences Corporation, Medtronic, Abbott Laboratories, Boston Scientific Corporation and JenaValve Technology, Inc.  2021/02/04 21:54:11 OpenPR
The heart valve devices market is expected to cross a US$ 16.2 Bn valuation by 2025, the end of the assessment period. The Fact.MR report states that the coronavirus outbreak will have a moderate impact on the heart valve devices
   Key Vendor Analyzed for Syringes & Cannulas Market | Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Edwards Lifesciences Corporation, Terumo Corporation  2021/02/02 21:10:06 OpenPR
An above-average rise at 4.0% volume CAGR is foreseen for the syringes & cannulas market over the period of forecast, 2018 to 2028, by a new Fact.MR study. Pervasiveness of syringes in terms of the market volume share continues to prevail,
   Cutting-edge firm with major Limerick plans hailed as ‘Great Place to Work’  2021/03/02 13:00:00 Limerick Leader
A FIRM which provides innovations for structural heart disease has received a top certification. Edwards Lifesciences Corporation, which currently employs 165 people in Shannon, and will ramp up to 600 staff when it opens its permanent facility in the National Technology Park, has received the Great
   Prosthetic Heart Valve Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026 | Edwards Lifesciences Corporation, Medtronic plc.  2021/02/12 04:06:52 OpenPR
Prosthetic Heart Valve Market Report 2020-2026 incorporates a complete examination of the current market. The report begins with the fundamental Prosthetic Heart Valve industry review and afterward goes into every single detail. Mechanical heart valve is an artificial heart valve implanted
   egnite, Inc. Launches as a Digital Health Company to Help Hospital Systems Improve the Quality of Patient Care  2021/02/10 13:00:00 Business Wire
ALISO VIEJO, Calif.--(BUSINESS WIRE)--egnite, a digital healthcare company, launched today with the goal to improve care for structural heart disease patients by delivering actionable insights through intuitive digital health platforms, proprietary artificial intelligence (A.I.) powered analytics and deep clinical expertise. egnite’s flagship solution, CardioCare, was developed at Edwards Lifesciences, and achieved several key innovation milestones and commercial successes over the past six yea
   Latest Insights on Heart Valve Devices Market Post-COVID? Fact.MR New Report Analyzes | Edwards Lifesciences Corporation, Medtronic, Abbott Laboratories, Boston Scientific Corporation and JenaValve Technology, Inc.  2021/02/04 21:54:11 OpenPR
The heart valve devices market is expected to cross a US$ 16.2 Bn valuation by 2025, the end of the assessment period. The Fact.MR report states that the coronavirus outbreak will have a moderate impact on the heart valve devices
   Key Vendor Analyzed for Syringes & Cannulas Market | Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Edwards Lifesciences Corporation, Terumo Corporation  2021/02/02 21:10:06 OpenPR
An above-average rise at 4.0% volume CAGR is foreseen for the syringes & cannulas market over the period of forecast, 2018 to 2028, by a new Fact.MR study. Pervasiveness of syringes in terms of the market volume share continues to prevail,

 関連キーワード  (先端医療機器_テクノロジ― 米国株 EW エドワ―ズライフサイエンス EW )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)